Pancreatic cancer has long been oncology’s most stubborn adversary. Fewer than 13% of patients survive five years after diagnosis, and for those whose disease has spread, the median is closer to six months. Surgery helps the minority whose tumors are caught early, but even then, recurrence is the rule rather than the exception.
Now, two experimental strategies are producing early results that researchers and regulators say could begin to change that calculus. One is a personalized mRNA vaccine, built from scratch for each patient’s tumor, that has kept immune cells on alert against pancreatic cancer for more than three years in a small trial. The other is a targeted antibody, already granted accelerated FDA approval, that shrinks tumors driven by a rare but actionable genetic alteration. Neither is a cure. But in a disease long defined by therapeutic dead ends, both represent genuine forward motion.
A vaccine tailored to one patient’s tumor
The mRNA vaccine, called autogene cevumeran, was developed through a collaboration between BioNTech and researchers at Memorial Sloan Kettering Cancer Center, led by surgeon-scientist Vinod Balachandran. It works on a principle borrowed from the COVID-19 mRNA playbook but applied in a fundamentally different way: instead of encoding a viral protein, each dose encodes up to 20 neoantigens, abnormal proteins produced by mutations unique to an individual patient’s tumor that are absent from healthy tissue.
The idea is to train the immune system’s killer T cells to recognize and destroy any cancer cells displaying those proteins, including microscopic clusters that may linger after surgery.
In a Phase 1 adjuvant trial, patients who had undergone surgical removal of pancreatic ductal adenocarcinoma received the checkpoint inhibitor atezolizumab, followed by the personalized vaccine, and then the chemotherapy regimen mFOLFIRINOX. Initial results, published in Nature in 2023, showed that roughly half of vaccinated patients mounted a strong, measurable T cell response to their tumor-specific neoantigens. Those responders had significantly longer recurrence-free survival than non-responders.
An extended follow-up analysis published in Nature in early 2025 confirmed that the vaccine-induced CD8+ T cells were not fading. At a median follow-up of just over three years, those immune cells remained detectable and functional in responders, still capable of recognizing the original tumor targets. In a cancer where most recurrences happen within the first two years after surgery, durable immune surveillance of that length is something researchers had not previously demonstrated.
A targeted antibody for a rare genetic driver
The second advance targets a different slice of the pancreatic cancer population entirely. In January 2025, the FDA granted accelerated approval to zenocutuzumab-zbco, sold as Bizengri, for adults with advanced, unresectable, or metastatic pancreatic adenocarcinoma harboring an NRG1 gene fusion who have already received at least one prior line of therapy.
NRG1 fusions are rare, occurring in roughly 0.2% to 0.5% of pancreatic cancers. But when present, they hijack a specific signaling pathway to fuel tumor growth. Zenocutuzumab is a bispecific antibody engineered to bind simultaneously to HER2 and HER3 receptors on the cell surface, blocking the abnormal signaling loop that NRG1 fusions exploit.
The approval was based on results from the open-label, multicohort eNRGy trial (NCT02912949), published in the New England Journal of Medicine. In NRG1 fusion-positive pancreatic adenocarcinoma cohorts, the drug produced meaningful tumor shrinkage and durable disease control in patients who had run out of standard options. The FDA’s accelerated pathway allows approval based on surrogate endpoints, such as objective response rate and duration of response, that are reasonably likely to predict clinical benefit.
What remains uncertain
Both treatments carry significant open questions, and patients and caregivers should weigh the excitement against what has not yet been proven.
For the mRNA vaccine: The Phase 1 trial was small and designed primarily to assess safety, feasibility, and immune response. All participants received an intensive combination of immunotherapy and chemotherapy alongside the vaccine, making it difficult to isolate the vaccine’s individual contribution to the survival difference between responders and non-responders. Full individual patient-level response and toxicity data beyond the aggregate survival curves and immune profiling in the Nature papers have not been published in granular detail.
The critical next step is already underway. A Phase 2 randomized trial called IMCODE003 (NCT05968326) is enrolling patients to compare the vaccine-plus-standard-treatment regimen against standard treatment alone. That trial is designed to answer the question the Phase 1 could not: does the vaccine itself extend survival? Results are not expected for several years.
Scaling the manufacturing process also remains a practical hurdle. Each vaccine must be custom-built from a patient’s tumor tissue, a process that currently requires specialized infrastructure and weeks of turnaround time. Whether that can be standardized for community oncology settings is an open question.
For zenocutuzumab: Accelerated approval is provisional by design. The FDA requires confirmatory data showing that the drug’s tumor-shrinkage signal translates into longer survival or improved symptoms. If confirmatory studies fail to verify a meaningful advantage, the approval can be withdrawn. The eNRGy trial pooled patients across multiple tumor types, and while the pancreatic cohort showed responses, the granular breakdown of outcomes by cancer type has not been reported with the depth that would allow full independent comparison.
Perhaps the biggest practical barrier is identification. Because NRG1 fusions are so rare, many oncologists, particularly in community practice, may not routinely order the comprehensive genomic sequencing panels needed to detect them. Turnaround times, insurance coverage for broad molecular testing, and simple awareness of the new indication all influence whether eligible patients are found and offered the drug.
How to read the evidence
The two treatments sit at different points on the evidence ladder. The mRNA vaccine has high-quality proof of biological activity: it reliably generates durable, tumor-specific T cell responses in a subset of patients. But biological activity is not the same as proven clinical efficacy. Until the randomized Phase 2 trial reports results, the survival signal remains promising but unconfirmed.
Zenocutuzumab is further along in regulatory terms but still provisional. The NEJM publication and the FDA’s own review documents provide solid evidence that the drug can shrink tumors and sustain responses in some NRG1 fusion-positive patients who have few alternatives. The absence of randomized comparative data and the reliance on surrogate endpoints mean the full picture of long-term benefit and risk is still forming.
For patients and families navigating these developments, two practical steps stand out. Those who are candidates for surgery should ask their oncologists whether clinical trials of personalized vaccines or other adjuvant immunotherapies are available at their treatment center, with the understanding that such approaches remain investigational. Those with advanced disease should discuss comprehensive molecular testing, including assays capable of detecting rare fusions like NRG1, to determine whether they might qualify for approved targeted drugs or ongoing trials.
Why these results matter for pancreatic cancer
Neither the mRNA vaccine nor zenocutuzumab has yet proven it can change overall survival statistics for pancreatic cancer at large. The vaccine applies to the subset of patients healthy enough for surgery; the antibody applies to a genomic sliver of advanced cases. Both come with unanswered questions about cost, access, and durability of benefit.
Yet the underlying science marks a real departure. For decades, pancreatic cancer resisted nearly every immunotherapy and targeted agent thrown at it. The vaccine trial demonstrated, for the first time, that the immune system can be trained to maintain years-long surveillance against pancreatic tumor cells. The zenocutuzumab approval showed that even in a cancer defined by its genetic complexity, identifying the right molecular target can unlock a meaningful response.
The next several years of randomized trials and confirmatory studies will determine whether these early signals hold up under rigorous testing. For now, they represent the strongest evidence in years that pancreatic cancer’s reputation as untreatable is no longer fully deserved.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
